Icon

BYSTOLIC (nda021742)- (EQ 2.5MG BASE,EQ 5MG BASE,EQ 10MG BASE,EQ 20MG BASE)

NEBIVOLOL HYDROCHLORIDE ALLERGAN
EQ 2.5MG BASE,EQ 5MG BASE,EQ 10MG BASE,EQ 20MG BASE
Yes No
2021-Dec-17 2012-Dec-17
None None
None No
BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
15 1 13
Total Other Developers 21
Drugs with Suitability No
EQ 2.5MG BASE ** ** Up - 7
EQ 5MG BASE ** ** Up - 7
EQ 10MG BASE ** ** Up - 8
EQ 20MG BASE ** ** Up - 8
NDA Sales Available Total Generic Sales Available
Yes 8
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** *** ****** *** ***************, ***. *********** *** *** **** **, ********, ********* (**) *****, ****** ****** (***) ***
****** ****** **** *** *** ****** **** ******* *********** **** ***, **** **. **-***, ****-**, ***, **********, *********, ********* ******, ***** (***) ***
****** ********* ****** ***** ************ ******* *********** **** **. ***/*, ***, ***/*, ***/* & ***/* ******* ****** ***** *****, *******, *****, ***** & *** ******, ***** (***) ***
****** ******* ******* *************** ******* *** *********** *********-******* *******, ******, ******-****, ****. *******, ******, ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********-******* *******, ******, ******-****, ****. *******, ******, ******* ******, ***** (***) ***
****** ****** ****** *** ****** *************** ******* *********** ****, ****** ****, ******, *********, ******* ******, ***** (***) ***
****** ********* ****** *** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ********* ** ****** ****** ******* *********** **** **. *-*** /* ***** *** - **** **, *******, ******* ******, ***** (***) ***
****** ******* ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ******* ****** ******* ****** ******* *********** ****-***, ******* *****, ****** **** ****, ***. ****** *******, ****** *****, *******, ******** ******* ******, ***** (***) ***
****** ******* ****** *** ******* *************** ******* *********** ***, *********, *****, ******* ****, ********** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** **. *, *****-*, ****** **** *** *********, ****, ****** ******* ******, ***** (***) ***
****** *** *** ************ ******* ******* *********** *********** ********, **** -** **. **'* (***** **) : ***, *** , ***, ***, ***, ***, ***, ***- *** *** *** ******** (*******), ********* (******),, ********** (********), ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.